

References:

1. Ponikowski P, et al. ESC Heart Fail. 2014;1(1):4-25.

2. Krumholz HM, et al. Circ Cardiovasc Qual Outcomes. 2009;2:407-413.

Butler J, et al. Congest Heart Fail. 2012;18(5 Suppl 1):S1-S3.
 Chioncel O, et al. Eur J Heart Fail. 2017;19:1242-1254;
 Granger BB, et al., J Card Fail. 2022;28:1355-1361.
 Butler J, et al. Eur J Heart Fail. 2021;23:1334-1342.
 Greene SJ, et al., J Am Coll Cardiol. 2018;72:351-366.
 Joseph S, et al. Eur Heart J. 2021;43:908-915.

Damasceno A, et al., Arch Intern Med. 2012;172:1386-1394.
 Čerlinskaitė K, et al. ESC Heart Fail. 2021;8:2473-2484.
 McDonagh TA, et al. Eur Heart J. 2021 Sep 21;42(36):3599-3726.
 Komajda M, et al. Eur J Heart Fail. 2016;18(5):514-22.
 Mebazaa A, et al. The Lancet. 2022; S0140-6736(22)02076-1.

3. Cowie MR, et al. Improving care for patients are acute heart failure [Internet; cited 2013].

Available from: http://www.oxfordhealthpolicyforum.org/reports/acute-heart-failure/improving-care-for-patients-with-acute-heart-failure.

All trademarks mentioned enjoy legal protection.

© 2022 Roche

Published by
Roche Diagnostics Scandinavia AB
Box 1228
171 23 Solna
MC-SE-02154



Primary outcomes


This material is intended for use by healthcare professionals.

Heart failure patients currently have high rates of readmission and mortality after discharge

The burden of heart failure



What are the challenges of post-discharge management?



STRONG-HF primary outcomes show significant reduction of all cause death or acute heart failure readmissions

Study Design STRVNG-HF 87 1,078 hospitals patients enrolled out of planned 1800° countries 18-85 vears old [†]Monitoring board of the study recommended to terminate the study early as it was considered unethical to continue with usual care. Hospital discharge assessment of clinical status, laboratory values hospitalisation and NT-proBNP concentrations Week 2 Week 6 Safety Safety Safety Half Half **Primary** Full optimal optima GDMT optima endpoint GDMT* **GDMT** care Randomized 1:1 N=1078 (1800 planned) all-cause Usual Follow-up and therapy adjustments per physician's usual practice

Results

n-converting enzyme inhibitors; AHF, acute heart failure; ARB, angiote

blockers; BB, beta blockers; GDMT, guideline-directed medical therapy; HF, heart failure; MRA,



Measuring NT-proBNP biomarker levels

is an integral part of the treatment strategy

in STRONG-HF.